SPONSOR

Sun Yat-sen University

Total Trials

Recruiting

Phases

Phase 2, Phase 3, Phase 1, Phase 2, Phase 1

Conditions studied: Diffuse Large B Cell Lymphoma Soft Tissue Sarcoma (STS)Osteosarcoma Breast Cancer Refractory Breast Carcinoma Temporomandibular Disorder Colorectal Cancer Liver Metastases Regorafenib Rectal Cancer Patients Robotic Assisted Intervention

Sun Yat-sen University is a clinical research sponsor with 43 registered studies on ClinicalTrials.gov, of which 43 are actively recruiting participants. Research covers conditions including Diffuse Large B Cell Lymphoma, Soft Tissue Sarcoma (STS), Osteosarcoma, Breast Cancer.

The trial portfolio spans Phase 2, Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Sun Yat-sen University

How many clinical trials has Sun Yat-sen University sponsored?

ClinicalMetric currently tracks 43 clinical trials sponsored by Sun Yat-sen University, of which 43 are actively recruiting participants. These trials cover conditions including Diffuse Large B Cell Lymphoma, Soft Tissue Sarcoma (STS), Osteosarcoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Sun Yat-sen University research focus on?

Sun Yat-sen University clinical trials span Diffuse Large B Cell Lymphoma, Soft Tissue Sarcoma (STS), Osteosarcoma, Breast Cancer, Refractory Breast Carcinoma, and additional conditions. The research pipeline includes Phase 2, Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Sun Yat-sen University clinical trial?

To participate in a Sun Yat-sen University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sun Yat-sen University trials with current recruitment status updated daily.

Sun Yat-sen University

Frequently Asked Questions — Sun Yat-sen University

Clinical Trials by Sun Yat-sen University

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

The New Serial Treatment of Temporomandibular Disorders

Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases

Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis

Lymphadenectomy in Early Ovarian Cancer

Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction

Multi-model Image of Doxycycline in TAO

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Safety and Efficacy of Pucotenlimab in pLECC

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

MItral Regurgitation Risk Assessment and CLinical modElling

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma

The Cold Ischemia Robot-assisted Partial Nephrectomy

Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening

Peritoneal Dialysis Registration System (PERSIST)

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

A Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma

Toripalimab Combined With CAV/IE Regimen

Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy

Epstein-Barr Virus and Cancer Risks

Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial